The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.
Mark J. Levis
Consultant or Advisory Role - Ambit BioSciences (U)
Giovanni Martinelli
No relevant relationships to disclose
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Hervé Dombret
No relevant relationships to disclose
Bjoern Steffen
No relevant relationships to disclose
Philippe H. Rousselot
No relevant relationships to disclose
Elihu Estey
No relevant relationships to disclose
Neil P. Shah
Research Funding - Ambit BioSciences
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Jorge E. Cortes
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Research Funding - Ambit BioSciences; Astellas Pharma